Doç. Dr. Neslihan Demirel Öğüt
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Psoriasis 6 publicationsSource: OpenAlex / PubMed MeSHView publications
- COVID-19 6 publications
- Chronic Urticaria 4 publications
- Acne Vulgaris 3 publications
- Skin Diseases 3 publications
- Hidradenitis Suppurativa 2 publications
- Alopecia Areata 2 publications
- Skin Neoplasms 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyDermatology and Venereologysaglik.gov.trFrom source
- Department name at the sourceDermatolojisaglik.gov.trFrom source
- InstitutionUşak Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
- Area of workPsoriasisExtracted from 6 publications · Model version —From source
- Publications51 publicationsEurope PMC, ORCIDFrom source
- ORCID0000-0001-5051-5481ORCIDFrom source
- Last synchronised5 November 2026 10:44https://usakeah.saglik.gov.tr/TR-1050583/doktorlarimiz.html#neslihan-demirel-ogutsaglik.gov.tr
Scientific work
Publications on Psoriasis
-
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE-I Study
International journal of dermatology, 2026
DOI 10.1111/ijd.70252 PMID 41474111 Open-access full textSource: Europe PMC
-
Malignancy burden and predictors in hidradenitis suppurativa tarda
Journal of the European Academy of Dermatology and Venereology : JEADV, 2026
DOI 10.1111/jdv.70715 PMID 42695529 Open-access full textSource: Europe PMC
-
The Impact of Hidradenitis Suppurativa on Sexual Function: A Multicentered Cross‐Sectional Study
International Journal of Dermatology, 2026
DOI 10.1111/ijd.70522 PMID 42268671 Open-access full textSource: ORCID
-
Caspase-8 Deficiency Unmasked by Refractory Psoriasiform Dermatitis: Marked Response to Dupilumab
Dermatitis®, 2026
DOI 10.1177/17103568261489011 PMID 42728888 Source: ORCID
-
Authors' Reply: Dermatologists' Way of Informative Content on Dermatology and Cosmetology on Social Media
Journal of Cosmetic Dermatology, 2026
DOI 10.1111/jocd.71190 Open-access full textSource: ORCID
-
Deucravacitinib in Psoriasis: Evidence, Gaps, and Place in Therapy
International Journal of Dermatology, 2026
DOI 10.1111/ijd.70170 PMID 41261382 Source: ORCID
-
Assessing the Role of Baseline Creatine Kinase Measurement Before Initiating Oral Isotretinoin in Acne Vulgaris Patients: Insights From a Retrospective Cohort of 1256 Individuals
Dermatologic Therapy, 2026
DOI 10.1155/dth/2680904 Open-access full textSource: ORCID
-
Hepatitis B Reactivation in Biologic‐Treated Moderate‐to‐Severe Psoriasis: A Real‐World Cohort Study With 534 Patient‐Years of Follow‐Up
Dermatologic Therapy, 2026
DOI 10.1155/dth/5653261 Open-access full textSource: ORCID
-
Predictors of relapse after omalizumab withdrawal in chronic spontaneous urticaria: Role of baseline autoimmunity and hematologic indices: CSU Relapse After Omalizumab Withdrawal
Allergy and Asthma Proceedings, 2026
DOI 10.2500/aap.2026.47.250089 PMID 41514184 Source: ORCID
-
Predictive Factors of Early Super-Response to Biologic Agents in Psoriasis: Insights from Real-World Evidence
Clinical, cosmetic and investigational dermatology, 2026
DOI 10.2147/ccid.s589513 PMID 41878550 Open-access full textSource: Europe PMC